Patent ID: 9528159
Filing Date: 2016-12-27
CPC Classification: C12Q,G01N

Claim Text:
1. A method of discriminating cervical dysplastic lesions from metaplastic lesions in a subject, the method comprising: (a) measuring an expression level of a high-risk HPV-associated nucleic acid in a sample collected from a cervical lesion in a subject; (b) measuring an expression level of at least one human protein marker selected from the group consisting of p14ARF and p16 (c) measuring an expression level of at least one human proliferation protein marker selected from a group consisting of MCM2, MCM5, CDC6, PCNA, and Ki67 in the sample; (d) determining that the lesion is dysplastic if there is a detectable level of the high-risk HPV-associated nucleic acid in the sample and there is at least one cell in the sample simultaneously expressing the protein marker of (b) and the proliferation protein marker of (c); and (e) determining that the lesion is metaplastic if there is a detectable level of the high-risk HPV-associated nucleic acid in the sample and if no cell in the sample co-expresses the protein marker of (b) and the proliferation protein marker of (c); thereby discriminating between dysplastic lesions from metaplastic lesions.